Glenmark Lobs Counterclaims At Teva In Coreg Suit

Law360, New York (December 2, 2008, 12:00 AM EST) -- Glenmark Pharmaceuticals Ltd. has moved into an offensive position in a patent spat over the preparation of a generic version of congestive heart failure treatment Coreg, accusing Teva Pharmaceuticals Industries Ltd. of engaging in “sham” litigation and violating federal antitrust laws.

Glenmark filed a handful of counterclaims against Teva on Monday in the U.S. District Court for the District of New Jersey, claiming that two of Teva's patents for the process of making carvedilol API, the active ingredient in Coreg, are not infringed, invalid and unenforceable...
To view the full article, register now.